6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline salt | 1426429-31-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline salt
• 英文别名: 3-Chloro-6-[[3,4-dioxo-2-(pentan-3-ylamino)cyclobuten-1-yl]amino]-2-[methoxy(methyl)sulfamoyl]phenolate;2-hydroxyethyl(trimethyl)azanium；3-chloro-6-[[3,4-dioxo-2-(pentan-3-ylamino)cyclobuten-1-yl]amino]-2-[methoxy(methyl)sulfamoyl]phenolate;2-hydroxyethyl(trimethyl)azanium
• CAS: 1426429-31-3
• 化学式: C₅H₁₄NO*C₁₇H₂₁ClN₃O₆S
• 分子量: 535.062
• InChiKey: RAWZXSCAJMQEHB-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.22
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  157
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-amino-6-chloro-2-hydroxy-N-methoxy-N-methylbenzene-1-sulfonamide 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 反应 7.5h， 生成 6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline salt
  参考文献：
  名称：

  Early Process Development of a Squaramide-Based CXCR2 Receptor Antagonist

  摘要：

  The synthesis of a CXCR2 antagonist is presented, highlighting the process changes made from research synthesis to clinical supply. The target compound is the choline salt of a nonsymmetrical squaramide, and the modifications to the synthetic route which have effect on chemical purity are discussed with reference to the isolated byproducts. Although drug substance quality was shown to increase following optimization of the linear sequence, an alternative one-pot, convergent sequence was introduced, which makes dual use of choline hydroxide as both base and salt-forming agent. The overall benefits of the strategic change is discussed in terms of overall yield and economy.

  DOI：

  10.1021/acs.oprd.5b00072

文献信息

• [EN] CHOLINE SALT OF AN ANTI - INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND<br/>[FR] SEL DE CHOLINE D'UN COMPOSÉ ANTI-INFLAMMATOIRE À BASE DE CYCLOBUTÈNEDIONE SUBSTITUÉ
  申请人：NOVARTIS AG

  公开号：WO2013030803A1

  公开（公告）日：2013-03-07

  6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N- methoxy-N-methyl-benzenesulfonamide choline, solid pharmaceutical compositions and oral dosage forms that contain said compound, and a method of using such compositions and oral dosage forms to treat people who have inflammatory, obstructive or allergic conditions and diseases.

  6-氯-3-[2-(1-乙基-丙基氨基)-3,4-二氧杂环丁-1-烯基氨基]-2-羟基-N-甲氧基-N-甲基苯磺酰胺胆碱，固体药物组合物和口服剂型，包含该化合物，并使用这些组合物和口服剂型治疗患有炎症、阻塞性或过敏性疾病的人的方法。
• 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
  申请人：Novartis AG

  公开号：US11185537B2

  公开（公告）日：2021-11-30

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.

  本公开提供了式(I′)化合物：或其药学上可接受的盐、水合物、溶液、原药、立体异构体或同系物，其中Ra、Rb、Rx、R1、R2、X2和q如本文所定义，以及制造和使用它们的方法。
• 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
  申请人：Novartis AG

  公开号：US11192877B2

  公开（公告）日：2021-12-07

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

  本公开提供了一种式(I′)化合物： 或其药学上可接受的盐、水合物、溶液、原药、立体异构体或同系物，其中 Rx、X1、X2 和 R1 如本文所定义，以及制造和使用它们的方法。
• COMBINATION THERAPIES
  申请人：Novartis AG

  公开号：EP3710053A1

  公开（公告）日：2020-09-23
• 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
  申请人：Novartis AG

  公开号：EP3924054A1

  公开（公告）日：2021-12-22